Informações de Celldex Therapeutics Inc

Mais detalhes de Celldex Therapeutics Inc Empresa

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.



Código da empresaCLDX

Nome da EmpresaCelldex Therapeutics Inc

Data de listagemMay 15, 1986

CEOMr. Anthony S. Marucci

Número de funcionários186

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 15

Endereço53 Frontage Road

CidadeHAMPTON

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal08827

Telefone19084547120

Sitehttps://celldex.com/

Código da empresaCLDX

Data de listagemMay 15, 1986

CEOMr. Anthony S. Marucci

Executivos da empresa Celldex Therapeutics Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

33.37K

-2.26%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

Mr. Herbert J. (Herb) Conrad

Independent Director

2.56K

--

Mr. James J. (Jim) Marino

Independent Director

2.20K

--

Mr. Keith L. Brownlie, CPA

Independent Director

666.00

--

Ms. Teri L. Lawver

Senior Vice President, Chief Commercial Officer

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Anthony S. Marucci

President, Chief Executive Officer, Director

40.64K

+1.48%

Mr. Freddy A. Jimenez, Esq., J.D.

Senior Vice President, General Counsel

33.37K

-2.26%

Dr. Diane C. Young, M.D.

Senior Vice President, Chief Medical Officer

17.11K

-63.67%

Dr. Margo Heath-Chiozzi, M.D.

Senior Vice President - Regulatory Affairs

13.74K

+2.70%

Ms. Elizabeth Crowley

Senior Vice President, Chief Product Development Officer

9.07K

--

Dr. Tibor Keler, Ph.D.

Executive Vice President, Chief Scientific Officer

7.36K

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: sáb, 16 de ago

Investidores

Tipos de investidores

Investidores

Proporção

Wellington Management Company, LLP

11.14%

Kynam Capital Management LP

9.19%

BlackRock Institutional Trust Company, N.A.

6.91%

Fidelity Management & Research Company LLC

5.95%

The Vanguard Group, Inc.

5.93%

Outro

60.89%

Investidores

Proporção

Wellington Management Company, LLP

11.14%

Kynam Capital Management LP

9.19%

BlackRock Institutional Trust Company, N.A.

6.91%

Fidelity Management & Research Company LLC

5.95%

The Vanguard Group, Inc.

5.93%

Outro

60.89%

Tipos de investidores

Investidores

Proporção

Investment Advisor

42.58%

Hedge Fund

32.92%

Investment Advisor/Hedge Fund

31.28%

Venture Capital

3.61%

Research Firm

2.78%

Pension Fund

0.39%

Bank and Trust

0.36%

Individual Investor

0.27%

Insurance Company

0.04%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

420

73.66M

110.92%

-14.44M

2025Q2

422

75.86M

114.26%

-13.90M

2025Q1

437

75.31M

113.46%

-13.68M

2024Q4

437

75.05M

113.05%

-8.14M

2024Q3

429

73.28M

110.59%

-7.16M

2024Q2

432

71.48M

107.86%

-10.62M

2024Q1

419

71.32M

108.50%

+952.72K

2023Q4

406

62.72M

112.33%

-412.93K

2023Q3

403

52.10M

110.18%

-8.63M

2023Q2

410

51.84M

109.57%

-7.47M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Wellington Management Company, LLP

5.23M

7.88%

-3.12M

-37.37%

Jun 30, 2025

Kynam Capital Management LP

6.10M

9.19%

-399.27K

-6.14%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.59M

6.91%

-38.52K

-0.83%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.95M

5.95%

+62.97K

+1.62%

Jun 30, 2025

The Vanguard Group, Inc.

3.94M

5.94%

+56.45K

+1.45%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.75M

5.65%

+398.14K

+11.88%

Jun 30, 2025

Commodore Capital LP

3.45M

5.2%

+100.00K

+2.99%

Jun 30, 2025

Bellevue Asset Management AG

3.31M

4.98%

+235.95K

+7.68%

Jun 30, 2025

Point72 Asset Management, L.P.

2.80M

4.22%

+180.55K

+6.89%

Jun 30, 2025

State Street Investment Management (US)

2.41M

3.62%

-400.86K

-14.28%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

Simplify Propel Opportunities ETF

3.32%

ALPS Medical Breakthroughs ETF

1.02%

Virtus LifeSci Biotech Clinical Trials ETF

0.92%

SPDR S&P Biotech ETF

0.65%

Direxion Daily S&P Biotech Bull 3X Shares

0.34%

Avantis US Small Cap Equity ETF

0.15%

First Trust Small Cap Growth AlphaDEX Fund

0.14%

Nuveen ESG Small-Cap ETF

0.14%

Fidelity Fundamental Small-Mid Cap ETF

0.13%

T Rowe Price Small-Mid Cap ETF

0.12%

Ver Mais

Simplify Propel Opportunities ETF

Proporção3.32%

ALPS Medical Breakthroughs ETF

Proporção1.02%

Virtus LifeSci Biotech Clinical Trials ETF

Proporção0.92%

SPDR S&P Biotech ETF

Proporção0.65%

Direxion Daily S&P Biotech Bull 3X Shares

Proporção0.34%

Avantis US Small Cap Equity ETF

Proporção0.15%

First Trust Small Cap Growth AlphaDEX Fund

Proporção0.14%

Nuveen ESG Small-Cap ETF

Proporção0.14%

Fidelity Fundamental Small-Mid Cap ETF

Proporção0.13%

T Rowe Price Small-Mid Cap ETF

Proporção0.12%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados